Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Valés-Gómez M[au]:

Search results

Items: 1 to 50 of 52

1.

Identification of the first cases of complete CD16A deficiency: association with persistent EBV infection.

Portilla AP, Moraru M, Moreno AB, Kolb P, García-Morato MB, Ranganath T, Esteso G, Gianelli C, Rodríguez-Pena R, Rodríguez RL, Torres-Canizales JM, Blish CA, Vales-Gomez M, Hengel H, Vilches C, Granados EL, Reyburn HT.

J Allergy Clin Immunol. 2020 Jan 14. pii: S0091-6749(20)30033-6. doi: 10.1016/j.jaci.2019.11.049. [Epub ahead of print]

PMID:
31953104
2.

BCG Therapy of Bladder Cancer Stimulates a Prolonged Release of the Chemoattractant CXCL10 (IP10) in Patient Urine.

Ashiru O, Esteso G, García-Cuesta EM, Castellano E, Samba C, Escudero-López E, López-Cobo S, Álvarez-Maestro M, Linares A, Ho MM, Leibar A, Martínez-Piñeiro L, Valés-Gómez M.

Cancers (Basel). 2019 Jul 4;11(7). pii: E940. doi: 10.3390/cancers11070940.

3.

Tetraspanin-decorated extracellular vesicle-mimetics as a novel adaptable reference material.

Lozano-Andrés E, Libregts SF, Toribio V, Royo F, Morales S, López-Martín S, Valés-Gómez M, Reyburn HT, Falcón-Pérez JM, Wauben MH, Soto M, Yáñez-Mó M.

J Extracell Vesicles. 2019 Mar 4;8(1):1573052. doi: 10.1080/20013078.2019.1573052. eCollection 2019.

4.

High sensitivity detection of extracellular vesicles immune-captured from urine by conventional flow cytometry.

Campos-Silva C, Suárez H, Jara-Acevedo R, Linares-Espinós E, Martinez-Piñeiro L, Yáñez-Mó M, Valés-Gómez M.

Sci Rep. 2019 Feb 14;9(1):2042. doi: 10.1038/s41598-019-38516-8.

5.

Exosome beads array for multiplexed phenotyping in cancer.

Jara-Acevedo R, Campos-Silva C, Valés-Gómez M, Yáñez-Mó M, Suárez H, Fuentes M.

J Proteomics. 2019 Apr 30;198:87-97. doi: 10.1016/j.jprot.2018.12.023. Epub 2018 Dec 28.

PMID:
30594577
6.

Immunoassays for scarce tumour-antigens in exosomes: detection of the human NKG2D-Ligand, MICA, in tetraspanin-containing nanovesicles from melanoma.

López-Cobo S, Campos-Silva C, Moyano A, Oliveira-Rodríguez M, Paschen A, Yáñez-Mó M, Blanco-López MC, Valés-Gómez M.

J Nanobiotechnology. 2018 May 2;16(1):47. doi: 10.1186/s12951-018-0372-z.

7.

NKG2H-Expressing T Cells Negatively Regulate Immune Responses.

Dukovska D, Fernández-Soto D, Valés-Gómez M, Reyburn HT.

Front Immunol. 2018 Mar 1;9:390. doi: 10.3389/fimmu.2018.00390. eCollection 2018.

8.

NKG2D-ligands: Putting everything under the same umbrella can be misleading.

Campos-Silva C, Kramer MK, Valés-Gómez M.

HLA. 2018 Jun;91(6):489-500. doi: 10.1111/tan.13246. Review.

PMID:
29521021
9.

New human combined immunodeficiency caused by interferon regulatory factor 4 (IRF4) deficiency inherited by uniparental isodisomy.

Bravo García-Morato M, Aracil Santos FJ, Briones AC, Blázquez Moreno A, Del Pozo Maté Á, Domínguez-Soto Á, Beato Merino MJ, Del Pino Molina L, Torres Canizales J, Marin AV, Vallespín García E, Feito Rodríguez M, Plaza López Sabando D, Jiménez-Reinoso A, Mozo Del Castillo Y, Sanz Santaeufemia FJ, de Lucas-Laguna R, Cárdenas PP, Casamayor Polo L, Coronel Díaz M, Valés-Gómez M, Roldán Santiago E, Ferreira Cerdán A, Nevado Blanco J, Corbí ÁL, Reyburn HT, Regueiro JR, López-Granados E, Rodríguez Pena R.

J Allergy Clin Immunol. 2018 May;141(5):1924-1927.e18. doi: 10.1016/j.jaci.2017.12.995. Epub 2018 Mar 2. No abstract available.

PMID:
29408330
10.

Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors.

López-Cobo S, Pieper N, Campos-Silva C, García-Cuesta EM, Reyburn HT, Paschen A, Valés-Gómez M.

Oncoimmunology. 2017 Nov 6;7(2):e1392426. doi: 10.1080/2162402X.2017.1392426. eCollection 2018.

11.

Innate immune recognition of double-stranded RNA triggers increased expression of NKG2D ligands after virus infection.

Esteso G, Guerra S, Valés-Gómez M, Reyburn HT.

J Biol Chem. 2017 Dec 15;292(50):20472-20480. doi: 10.1074/jbc.M117.818393. Epub 2017 Oct 6.

12.

Analysis of the recovery of CD247 expression in a PID patient: insights into the spontaneous repair of defective genes.

Blázquez-Moreno A, Pérez-Portilla A, Agúndez-Llaca M, Dukovska D, Valés-Gómez M, Aydogmus C, Ikinciogullari A, Regueiro JR, Reyburn HT.

Blood. 2017 Sep 7;130(10):1205-1208. doi: 10.1182/blood-2017-01-762864. Epub 2017 Jul 25.

PMID:
28743717
13.

Characterization of a human anti-tumoral NK cell population expanded after BCG treatment of leukocytes.

García-Cuesta EM, Esteso G, Ashiru O, López-Cobo S, Álvarez-Maestro M, Linares A, Ho MM, Martínez-Piñeiro L, T Reyburn H, Valés-Gómez M.

Oncoimmunology. 2017 Feb 21;6(4):e1293212. doi: 10.1080/2162402X.2017.1293212. eCollection 2017.

14.

Glycosyl-Phosphatidyl-Inositol (GPI)-Anchors and Metalloproteases: Their Roles in the Regulation of Exosome Composition and NKG2D-Mediated Immune Recognition.

López-Cobo S, Campos-Silva C, Valés-Gómez M.

Front Cell Dev Biol. 2016 Sep 12;4:97. doi: 10.3389/fcell.2016.00097. eCollection 2016. Review.

15.

Development of a rapid lateral flow immunoassay test for detection of exosomes previously enriched from cell culture medium and body fluids.

Oliveira-Rodríguez M, López-Cobo S, Reyburn HT, Costa-García A, López-Martín S, Yáñez-Mó M, Cernuda-Morollón E, Paschen A, Valés-Gómez M, Blanco-López MC.

J Extracell Vesicles. 2016 Aug 12;5:31803. doi: 10.3402/jev.v5.31803. eCollection 2016.

16.

A short half-life of ULBP1 at the cell surface due to internalization and proteosomal degradation.

Fernández-Messina L, Reyburn HT, Valés-Gómez M.

Immunol Cell Biol. 2016 May;94(5):479-85. doi: 10.1038/icb.2016.2. Epub 2016 Jan 6.

PMID:
26732147
17.

Natural killer cell hyporesponsiveness and impaired development in a CD247-deficient patient.

Valés-Gómez M, Esteso G, Aydogmus C, Blázquez-Moreno A, Marín AV, Briones AC, Garcillán B, García-Cuesta EM, López Cobo S, Haskologlu S, Moraru M, Cipe F, Dobbs K, Dogu F, Parolini S, Notarangelo LD, Vilches C, Recio MJ, Regueiro JR, Ikinciogullari A, Reyburn HT.

J Allergy Clin Immunol. 2016 Mar;137(3):942-5.e4. doi: 10.1016/j.jaci.2015.07.051. Epub 2015 Nov 2. No abstract available.

PMID:
26542031
18.

NKG2D is a Key Receptor for Recognition of Bladder Cancer Cells by IL-2-Activated NK Cells and BCG Promotes NK Cell Activation.

García-Cuesta EM, López-Cobo S, Álvarez-Maestro M, Esteso G, Romera-Cárdenas G, Rey M, Cassady-Cain RL, Linares A, Valés-Gómez A, Reyburn HT, Martínez-Piñeiro L, Valés-Gómez M.

Front Immunol. 2015 Jun 8;6:284. doi: 10.3389/fimmu.2015.00284. eCollection 2015.

19.

Transfer of the human NKG2D ligands UL16 binding proteins (ULBP) 1-3 is related to lytic granule release and leads to ligand retransfer and killing of ULBP-recipient natural killer cells.

López-Cobo S, Romera-Cárdenas G, García-Cuesta EM, Reyburn HT, Valés-Gómez M.

Immunology. 2015 Sep;146(1):70-80. doi: 10.1111/imm.12482. Epub 2015 Jun 25.

20.

The Impact of Glycosyl-Phosphatidyl-Inositol Anchored MICA Alleles on Novel NKG2D-Based Therapies.

Valés-Gómez M.

Front Immunol. 2015 Apr 27;6:193. doi: 10.3389/fimmu.2015.00193. eCollection 2015. Review. No abstract available.

21.

Altered microRNA expression after infection with human cytomegalovirus leads to TIMP3 downregulation and increased shedding of metalloprotease substrates, including MICA.

Esteso G, Luzón E, Sarmiento E, Gómez-Caro R, Steinle A, Murphy G, Carbone J, Valés-Gómez M, Reyburn HT.

J Immunol. 2014 Aug 1;193(3):1344-52. doi: 10.4049/jimmunol.1303441. Epub 2014 Jun 27.

22.

A GPI anchor explains the unique biological features of the common NKG2D-ligand allele MICA*008.

Ashiru O, López-Cobo S, Fernández-Messina L, Pontes-Quero S, Pandolfi R, Reyburn HT, Valés-Gómez M.

Biochem J. 2013 Sep 1;454(2):295-302. doi: 10.1042/BJ20130194.

PMID:
23772752
23.

Human NKG2D-ligands: cell biology strategies to ensure immune recognition.

Fernández-Messina L, Reyburn HT, Valés-Gómez M.

Front Immunol. 2012 Sep 25;3:299. doi: 10.3389/fimmu.2012.00299. eCollection 2012.

24.

Palmitoylation of MICA, a ligand for NKG2D, mediates its recruitment to membrane microdomains and promotes its shedding.

Agüera-González S, Gross CC, Fernández-Messina L, Ashiru O, Esteso G, Hang HC, Reyburn HT, Long EO, Valés-Gómez M.

Eur J Immunol. 2011 Dec;41(12):3667-76. doi: 10.1002/eji.201141645. Epub 2011 Nov 3.

25.

The human NKG2D ligand ULBP2 can be expressed at the cell surface with or without a GPI anchor and both forms can activate NK cells.

Fernández-Messina L, Ashiru O, Agüera-González S, Reyburn HT, Valés-Gómez M.

J Cell Sci. 2011 Feb 1;124(Pt 3):321-7. doi: 10.1242/jcs.076042. Epub 2011 Jan 11.

26.

Differential mechanisms of shedding of the glycosylphosphatidylinositol (GPI)-anchored NKG2D ligands.

Fernández-Messina L, Ashiru O, Boutet P, Agüera-González S, Skepper JN, Reyburn HT, Valés-Gómez M.

J Biol Chem. 2010 Mar 19;285(12):8543-51. doi: 10.1074/jbc.M109.045906. Epub 2010 Jan 14.

27.

Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes.

Ashiru O, Boutet P, Fernández-Messina L, Agüera-González S, Skepper JN, Valés-Gómez M, Reyburn HT.

Cancer Res. 2010 Jan 15;70(2):481-9. doi: 10.1158/0008-5472.CAN-09-1688. Epub 2010 Jan 12.

28.

Brief residence at the plasma membrane of the MHC class I-related chain B is due to clathrin-mediated cholesterol-dependent endocytosis and shedding.

Agüera-González S, Boutet P, Reyburn HT, Valés-Gómez M.

J Immunol. 2009 Apr 15;182(8):4800-8. doi: 10.4049/jimmunol.0800713.

29.

Cutting edge: the metalloproteinase ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein.

Boutet P, Agüera-González S, Atkinson S, Pennington CJ, Edwards DR, Murphy G, Reyburn HT, Valés-Gómez M.

J Immunol. 2009 Jan 1;182(1):49-53.

30.

Selective induction of expression of a ligand for the NKG2D receptor by proteasome inhibitors.

Valés-Gómez M, Chisholm SE, Cassady-Cain RL, Roda-Navarro P, Reyburn HT.

Cancer Res. 2008 Mar 1;68(5):1546-54. doi: 10.1158/0008-5472.CAN-07-2973.

31.

Intracellular trafficking of the HCMV immunoevasin UL16 depends on elements present in both its cytoplasmic and transmembrane domains.

Valés-Gómez M, Reyburn HT.

J Mol Biol. 2006 Nov 10;363(5):908-17. Epub 2006 Aug 30.

PMID:
16996537
32.

Transfer of NKG2D and MICB at the cytotoxic NK cell immune synapse correlates with a reduction in NK cell cytotoxic function.

Roda-Navarro P, Vales-Gomez M, Chisholm SE, Reyburn HT.

Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11258-63. Epub 2006 Jul 18.

33.

The human cytomegalovirus glycoprotein UL16 traffics through the plasma membrane and the nuclear envelope.

Valés-Gómez M, Winterhalter A, Roda-Navarro P, Zimmermann A, Boyle L, Hengel H, Brooks A, Reyburn HT.

Cell Microbiol. 2006 Apr;8(4):581-90.

PMID:
16548884
34.

CD161 (human NKR-P1A) signaling in NK cells involves the activation of acid sphingomyelinase.

Pozo D, Valés-Gómez M, Mavaddat N, Williamson SC, Chisholm SE, Reyburn H.

J Immunol. 2006 Feb 15;176(4):2397-406.

36.
37.

The role of zinc in the binding of killer cell Ig-like receptors to class I MHC proteins.

Valés-Gómez M, Erskine RA, Deacon MP, Strominger JL, Reyburn HT.

Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1734-9. Epub 2001 Feb 6.

38.

Interaction between the human NK receptors and their ligands.

Valés-Gómez M, Reyburn H, Strominger J.

Crit Rev Immunol. 2000;20(3):223-44. Review.

PMID:
10968372
39.

Definition of polymorphic residues on killer Ig-like receptor proteins which contribute to the HLA-C binding site.

Richardson J, Reyburn HT, Luque I, Valés-Gómez M, Strominger JL.

Eur J Immunol. 2000 May;30(5):1480-5.

40.

Molecular analyses of the interactions between human NK receptors and their HLA ligands.

Valés-Gómez M, Reyburn H, Strominger J.

Hum Immunol. 2000 Jan;61(1):28-38. Review.

PMID:
10658975
41.

Human leucocyte antigen-G and its recognition by natural killer cells.

Pazmany L, Mandelboim O, Vales-Gomez M, Davis DM, Becker TC, Reyburn HT, Seebach JD, Hill JA, Strominger JL.

J Reprod Immunol. 1999 Jul;43(2):127-37. Review. No abstract available.

PMID:
10479049
42.

Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E.

Valés-Gómez M, Reyburn HT, Erskine RA, López-Botet M, Strominger JL.

EMBO J. 1999 Aug 2;18(15):4250-60.

43.

Differential binding to HLA-C of p50-activating and p58-inhibitory natural killer cell receptors.

Valés-Gómez M, Reyburn HT, Erskine RA, Strominger J.

Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14326-31.

44.

Kinetics of interaction of HLA-C ligands with natural killer cell inhibitory receptors.

Valés-Gómez M, Reyburn HT, Mandelboim M, Strominger JL.

Immunity. 1998 Sep;9(3):337-44. Erratum in: Immunity 1998 Dec;9(6):892.

45.

Multiple receptors for HLA-G on human natural killer cells.

Mandelboim O, Pazmany L, Davis DM, Valés-Gómez M, Reyburn HT, Rybalov B, Strominger JL.

Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14666-70.

46.

Self and viral peptides can initiate lysis by autologous natural killer cells.

Mandelboim O, Wilson SB, Valés-Gómez M, Reyburn HT, Strominger JL.

Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4604-9.

47.

The class I MHC homologue of human cytomegalovirus inhibits attack by natural killer cells.

Reyburn HT, Mandelboim O, Valés-Gómez M, Davis DM, Pazmany L, Strominger JL.

Nature. 1997 Apr 3;386(6624):514-7.

PMID:
9087413
48.

The binding site of NK receptors on HLA-C molecules.

Mandelboim O, Reyburn HT, Sheu EG, Vales-Gomez M, Davis DM, Pazmany L, Strominger JL.

Immunity. 1997 Mar;6(3):341-50.

49.

Human NK cells: their ligands, receptors and functions.

Reyburn H, Mandelboim O, Valés-Goméz M, Sheu EG, Pazmany L, Davis DM, Strominger JL.

Immunol Rev. 1997 Feb;155:119-25. Review.

PMID:
9059887
50.

Enhancement of class II-restricted T cell responses by costimulatory NK receptors for class I MHC proteins.

Mandelboim O, Davis DM, Reyburn HT, Valés-Gómez M, Sheu EG, Pazmany L, Strominger JL.

Science. 1996 Dec 20;274(5295):2097-100.

PMID:
8953044

Supplemental Content

Loading ...
Support Center